output-onlinepngtools.png
Overview
Scope
Amenities
Media
Contact

Radiopharmaceutical Therapy Frequently Asked Questions (FAQ)

Wellness Programme FAQ
Radiopharmaceutical FAQ
Diet and Nutrition FAQ

WHAT IS XOFIGO?

Xofigo is Radium 223 Dichloride and is an alpha particle-emitting radioactive therapeutic agent. It is used for treatment of patient with prostate cancer.



WHO IS XOFIGO SUITABLE FOR?

Xofigo is suitable for metastatic castration-resistant prostate cancer (mCRPC) patient on second-generation hormonal therapy has: • Bone metastases, and no visceral metastases • Suspected disease progression: — Increase in biomarker levels, such as prostate-specific antigen (PSA) and/or alkaline phosphatase (ALP) — Progression seen on imaging scans — Emerging symptoms (use of analgesics)



HOW LONG IS THE XOFIGO TREATMENT?

• Treatment plan: 6 injections total • Slow intravenous (IV) injection over 1 minute • Treatment can be completed in 5 months • Patients may return home after the injection



WHAT DO I NEED TO BRING FOR TREATMENT?

ID and/or Passport.
This original Preparation Instruction Sheet
Previous/recent relevant reports or CD, if available.
Previous / recent blood test results, if available.
DO NOT bring valuable belongings, including jewellery, etc SPECIAL ARRANGEMENT If patients are on wheel chair / trolley, please come with:

  • Accompanying staff nurse familiar with patients' medical background
  • Existing IV line / cannula, if any
  • Urine bag, where applicable, should be emptied.
  • Parking for ambulances are available at Level B2 carpark.

Urinal / bedpan / extra diapers when necessary for toileting care.